GFAP and Parkinson disease: Remarkably, the astrocytic organization, determined by GFAP staining, was severely disrupted, and GFAP levels were significantly elevated (~42%) in PD patients carrying the LRRK2 G2019S mutation, indicative of reactive gliosis (Figure 1B-C).